Advanced in Febrile Neutropenia

Jane M. Beith

Missenden Rd, 
Camperdown, NSW, AU 
Advanced in Febrile Neutropenia
Missenden Rd, 
Camperdown, NSW, AU 
OverviewLocationsClinical Research

Overview

Jane Beith practices in Camperdown, Australia. Ms. Beith is rated as an Advanced expert by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Breast Cancer, Lymphedema, Febrile Neutropenia, Mastectomy, and Oophorectomy.

Her clinical research consists of co-authoring 97 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Febrile Neutropenia.

Gender
Female

Locations

Missenden Rd, Camperdown, NSW, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3
View 1 Less Clinical Trial

97 Total Publications

Assessment of long-term alopecia after adjuvant taxane therapy for early breast cancer: a cross-sectional survey.
Assessment of long-term alopecia after adjuvant taxane therapy for early breast cancer: a cross-sectional survey.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: January 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Beith's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile